U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07898800) titled 'Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy' on Oct. 20.
Brief Summary: Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults. As an secondary objectives, the trial will also assess the number of participants receiving the maximum intended DM-101PX dose and to assess the effect of treatment with DM-101PX compared with placebo on blood allergy biomarkers. Expanded access to the study treatment is not available.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Cond...